Skip Navigation



Europace Advance Access published online on October 29, 2009
Europace, doi:10.1093/europace/eup328
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nishida, K.
Right arrow Articles by Nattel, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nishida, K.
Right arrow Articles by Nattel, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.

REVIEW

Animal models for atrial fibrillation: clinical insights and scientific opportunities

Kunihiro Nishida1, Georghia Michael1, Dobromir Dobrev2 and Stanley Nattel1,*

1 Department of Medicine, Montréal Heart Institute, Université de Montréal, Montréal, 5000 Belanger Street East, Montreal, Quebec, Canada H1T 1C8; 2 Department of Pharmacology and Toxicology, Dresden University of Technology, Dresden, Germany

Atrial fibrillation (AF) is the most common arrhythmia in clinical practice. A variety of animal models have been used to study the pathophysiology of AF, including molecular basis, ion-current determinants, anatomical features, and macroscopic mechanisms. In addition, animal models play a key role in the development of new therapeutic approaches, whether drug-based, molecular therapeutics, or device-related. This article discusses the various types of animal models that have been used for AF research, reviews the principle mechanisms governing atrial arrhythmias in each model, and provides some guidelines for model selection for various purposes.

Key Words: Arrhythmias, Anti-arrhythmia therapy, Anti-arrhythmic drugs, Ablation, Re-entry, Triggered activity, Transgenic, Knockout

* Corresponding author. Tel: +1 514 376 3330, Fax: +1 514 376 1355, Email: stanley.nattel{at}icm-mhi.org

Manuscript submitted 24 September 2009. Accepted after revision 27 September 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.